Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2374 • 2012 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Gastrointestinal Involvement in Behcet’s Syndrome: Experience in A Dedicated Center
Ibrahim Hatemi¹, Gulen Hatemi², Yusuf Erzin¹, Aykut Ferhat Celik¹ and Hasan Yazici³, ¹Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey
Background/Purpose: Gastrointestinal involvement can be a severe complication resulting in perforation and massive bleeding. Controlled data regarding treatment is lacking and long term prognosis is…
Abstract Number: 2376 • 2012 ACR/ARHP Annual Meeting
Behcet’s Disease: Combination of Pulse Cyclophosphamide, Azathioprine, and Prednisolone for the Treatment of Retinal Vasculitis; Longitudinal Study On 10 Years
Fereydoun Davatchi¹, Farhad Shahram², Bahar Sadeghi Abdollahi², Hormoz Shams², Abdolhadi Nadji², Massoomeh Akhlaghi², Tahereh Faezi² and Farimah Ashofteh², ¹Rheumatology Research Ctr and Department of Rheumatology, Shariati Hospital-Tehran Univ, Tehran, Iran, ²Rheumatology, Behcet's Unit, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Background/Purpose: Ocular lesions of Behcet’s Disease (BD), need aggressive treatment to prevent severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents…
Abstract Number: 1005 • 2012 ACR/ARHP Annual Meeting
The Identification of Pathway Markers in Behcet’s Disease Using Genomewide Association Data From Two Different Populations
Burcu Bakir-Gungor¹, Elaine Remmers², Daniel L. Kastner², Akira Meguro³, Nobuhisa Mizuki⁴, Ahmet Gul⁵ and Osman Ugur Sezerman⁶, ¹Department of Genetics and Bioinformatics, Faculty of Arts and Sciences, Bahcesehir University, Istanbul, Turkey, ²Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁶Biological Sciences and Bioengineering, Faculty of Engineering and Natural Sciences, Sabancı University, Istanbul, Turkey
Background/Purpose: Behcet's disease (BD) is a multi-system inflammatory disease, characterized by recurrent exacerbations affecting several organs including orogenital mucosa, eyes and skin. Two recent genome-wide…
Abstract Number: 858 • 2012 ACR/ARHP Annual Meeting
Dense Genotyping, Imputation, and Regression Analysis Identifies Multiple Independent Genetic Susceptibility Loci within the HLA Region in Behcet’s Disease
Travis Hughes¹, Adam Adler², Patrick S. Coit¹, Vuslat Yilmaz³, Kenan Aksu⁴, Nursen Duzgun⁵, Gokhan Keser⁴, Ayse Cefle⁶, Ayten Yazici⁶, Andac Ergen⁷, Erkan Alpsoy⁸, Carlo Salvarani⁹, Bruno Casali¹⁰, Ina Koetter¹¹, Javier Gutierrez-Achury¹², Cisca Wijmenga¹², Haner Direskeneli¹³, Guher Saruhan-Direskeneli¹⁴ and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Istanbul University, Istanbul Faculty of Medicine, Department of Physiology, Istanbul, Turkey, ⁴Dept. of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, ⁵Ankara University, Ankara, Turkey, ⁶Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, ⁷Okmeydaný Research and Education Hospital, Istanbul, Turkey, ⁸Department of Dermatology, Akdeniz University, Antalya, Turkey, ⁹Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Molecular Biology Laboratory, Arcispedale S. Maria Nuova,, Reggio Emilia, Italy, ¹¹Robert Bosch Krankenhaus, Stuttgart, Germany, ¹²Department of Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ¹³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ¹⁴Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The genetic association between HLA-B51 and Behcet’s disease is well established. However, localizing this genetic effect and exploring additional susceptibility loci within the HLA…
Abstract Number: 203 • 2012 ACR/ARHP Annual Meeting
Clinical Course Factors Associated with Outcome of Monoarthritis : A Retrospective Study of 173 Cases
Hyemin Jeong¹, Eun-Jung Park¹, Jiwon Hwang¹, Ji Young Chai², Joong Kyong Ahn³, Eun-Mi Koh⁴ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, ³Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea
Background/Purpose: To evaluate the clinical features and outcomes in patients with monoarthritis and to investigate predictive factors associated with the clinical course in terms of…
Abstract Number: 181 • 2012 ACR/ARHP Annual Meeting
Thiopurine S-Methyltransferase Levels in Patients with Behçet’s Disease
Hakan Emmungil¹, Melike Kalfa², Raika Durusoy³, Figen Yargucu Zihni², Gokhan Keser⁴ and Kenan Aksu², ¹Rheumatology, Mersin State Hospital, Mersin, Turkey, ²Dept. of Internal Medicine, Division of Rheumatology, Ege University, Dept. of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, ³Department of Public Health, Ege University, Department of Public Health, Ege University, Izmir, Turkey, ⁴Dept. of Internal Medicine, Division of Rheumatology, Ege University School of Medicine, Izmir, Turkey
Background/Purpose: Azathioprine (AZA) is an immunosuppressive agent which is widely used not only for the treatment of Behcet’s disease (BD), but also for the treatment…
Abstract Number: 183 • 2012 ACR/ARHP Annual Meeting
A Strong Association Between HLA-A*26 and Behçet’s Syndrome in Japanese Patients: From Two-Center Cohort Study of Behçet’s Syndrome
Tatsuo Kobayashi¹, Mitsumasa Kishimoto², Kazuki Yoshida¹, Yuri Ohara³, Hiroto Nakano¹, Masahiro Minoda¹, Hideto Oshikawa¹ and Kazuo Matsui¹, ¹Rheumatology, Kameda Medical Center, Kamogawa City, Chiba, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ³Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan
Background/Purpose: An association between Behçet’s Syndrome (BS) and HLA-B*51 is widely reported among many different ethnic groups. Recently, a few reports from Taiwan, Greece and…
Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Yoshitaka Kimura¹, Kurumi Asako², Hirotoshi Kikuchi², Akiteru Takeuchi³ and Hajime Kono², ¹Department of Internal Medicine, Teikyo University school of medecine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³6-7-8 Arakawa, Tokyo, Japan
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…
Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
M. Victoria Hernández¹, Marina Mesquida², Gerard Espinosa³, Victor Llorens², Laura Pelegrin², Juan D. Cañete⁴, Ricard Cervera⁵, Alfredo M. Adan² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ³Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].